Announced details
Treatment of pediatric patients with achondroplasia (ACH) aged 2 to 14 years; domestic Phase III clinical trial
Cumulative subject enrollment as of today: 3 subjects (enrollment of 2 additional subjects completed)
Orphan drug designation
Ministry of Health, Labour and Welfare
All 16 sites (preparations for conducting the clinical trial completed)
No impact on full-year earnings for the fiscal year ending March 2027
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | umedaptanib pegol（RBM-007） |
| Applicable area | Treatment of pediatric patients with achondroplasia (ACH) aged 2 to 14 years; domestic Phase III clinical trial |
| Award/certification name | Orphan drug designation |
| Awarding / certifying body | Ministry of Health, Labour and Welfare |
| Location scale | All 16 sites (preparations for conducting the clinical trial completed) |
| Usage history | Cumulative subject enrollment as of today: 3 subjects (enrollment of 2 additional subjects completed) |
| Impact on Business Performance | No impact on full-year earnings for the fiscal year ending March 2027 |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Subject enrollment is being promoted in cooperation with each participating medical institution to achieve the target number of subjects.